Loading...
Header Logo
Keywords
Last Name
Institution

SHUBHAM PANT

TitleAssociate Professor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 Jun; 271(6):996-1002. PMID: 31895709.
      View in: PubMed
    2. Perri G, Prakash L, Malleo G, Caravati A, Varadhachary GR, Fogelman D, Pant S, Koay EJ, Herman J, Maggino L, Milella M, Kim M, Ikoma N, Tzeng CW, Salvia R, Lee JE, Bassi C, Katz MHG. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Ann Surg Oncol. 2020 Apr 07. PMID: 32266574.
      View in: PubMed
    3. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 Mar; 8(1). PMID: 32188704.
      View in: PubMed
    4. Rogers JE, Mizrahi JD, Shroff RT, Nelson DA, Tu J, Javle MM, Wolff RA, Pant S. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. J Gastrointest Oncol. 2020 Feb; 11(1):55-60. PMID: 32175105.
      View in: PubMed
    5. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504. PMID: 31932214.
      View in: PubMed
    6. Mizrahi J, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol. 2020; 1244:93-106. PMID: 32301012.
      View in: PubMed
    7. Pant S, Maitra A, Yap TA. PARP inhibition - opportunities in pancreatic cancer. Nat Rev Clin Oncol. 2019 10; 16(10):595-596. PMID: 31332344.
      View in: PubMed
    8. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 Nov; 20(11):1544-1555. PMID: 31563517.
      View in: PubMed
    9. Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253. PMID: 31533818.
      View in: PubMed
    10. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158. PMID: 31445783.
      View in: PubMed
    11. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2019 Jul 03. PMID: 31274655.
      View in: PubMed
    12. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348. PMID: 30869638.
      View in: PubMed
    13. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018 11 12; 34(5):775-791.e3. PMID: 30423297.
      View in: PubMed
    14. Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, Tanwar P, Khan A, Javle M, Hassan MM, Pant S, De Aretxabala X, Sirohi B, Rajaraman P, Kaur T, Rath GK. Genetic landscape of gallbladder cancer: Global overview. Mutat Res. 2018 Oct - Dec; 778:61-71. PMID: 30454684.
      View in: PubMed
    15. Pant S, Hubbard J, Martinelli E, Bekaii-Saab T. Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Crit Rev Oncol Hematol. 2018 Oct; 130:78-91. PMID: 30196915.
      View in: PubMed
    16. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291. PMID: 29668571.
      View in: PubMed
    17. Lam M, Pant S, Yap TA. Combination drug development in BRAF mutant colorectal cancer. Oncoscience. 2018 Mar; 5(3-4):51-53. PMID: 29854866.
      View in: PubMed
    18. Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424. PMID: 29695765.
      View in: PubMed
    19. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008.
      View in: PubMed
    20. Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN. A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. Clin Cancer Res. 2018 07 15; 24(14):3253-3262. PMID: 29636360.
      View in: PubMed
    21. Aghajanian C, Bell-McGuinn KM, Burris HA, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs. 2018 12; 36(6):1016-1025. PMID: 29611022.
      View in: PubMed
    22. Zhou X, Pant S, Nemunaitis J, Craig Lockhart A, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargfrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. Invest New Drugs. 2018 04; 36(2):248-258. PMID: 28852909.
      View in: PubMed
    23. Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Craig Lockhart A, Goodman D, Huebner D, Mould DR, Venkatakrishnan K. Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. Invest New Drugs. 2018 04; 36(2):240-247. PMID: 28819760.
      View in: PubMed
    24. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Jul 20. PMID: 28729355.
      View in: PubMed
    25. Pant S, Patel M, Kurkjian C, Hemphill B, Flores M, Thompson D, Bendell J. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Invest. 2017 Aug 09; 35(7):463-472. PMID: 28662341.
      View in: PubMed
    26. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2016 12; 39(6):614-618. PMID: 25068471.
      View in: PubMed
    27. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. PMID: 27528724.
      View in: PubMed
    28. Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel MR, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Lockhart AC, Tan E, Yang S, Carlson G, Scott JW, Sharma S. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927. PMID: 27681579.
      View in: PubMed
    29. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016 10; 61:31-40. PMID: 27688102.
      View in: PubMed
    30. Phan M, Jones S, Jenkins J, Pant S, Khawandanah M. Pancreatic GIST in a Patient with Limited Stage Small Cell Lung Cancer: A Case Report and Review of Published Cases. Case Rep Oncol Med. 2016; 2016:9604982. PMID: 27579203.
      View in: PubMed
    31. Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 06; 77(6):1275-83. PMID: 27151157.
      View in: PubMed
    32. Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Mol Ther. 2016 Jun; 24(6):1150-1158. PMID: 27039845.
      View in: PubMed
    33. Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BKR, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ESM, Chan EM, Bendell JC. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer. 2016 Mar; 56:1-9. PMID: 26798966.
      View in: PubMed
    34. Bendell JC, Jones SF, Hart L, Pant S, Moyhuddin A, Lane CM, Earwood C, Murphy P, Patton J, Penley WC, Thompson D, Infante JR. A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. Cancer Invest. 2015; 33(10):477-82. PMID: 26460795.
      View in: PubMed
    35. Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel). 2015 Aug 10; 7(3):1499-542. PMID: 26266422.
      View in: PubMed
    36. Ahmad B, Pierson N, Adnan MM, Phan M, Jenkins J, Pant S, Cherry M, Khawandanah M. Distant skin metastases as primary presentation of gastric cancer. J Community Support Oncol. 2015 Apr; 13(4):156-8. PMID: 26102608.
      View in: PubMed
    37. Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One. 2015; 10(2):e0118933. PMID: 25723399.
      View in: PubMed
    38. Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol. 2015 Apr; 55(4):392-400. PMID: 25449654.
      View in: PubMed
    39. Bendell JC, Patel MR, Infante JR, Kurkjian CD, Jones SF, Pant S, Burris HA, Moreno O, Esquibel V, Levin W, Moore KN. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 2015 Apr 01; 121(7):1056-63. PMID: 25411085.
      View in: PubMed
    40. Khawandanah M, Baxley A, Pant S. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. J Oncol Pharm Pract. 2015 Jun; 21(3):232-7. PMID: 24627343.
      View in: PubMed
    41. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6. PMID: 24633933.
      View in: PubMed
    42. Pant S, Burris HA, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93. PMID: 23525756.
      View in: PubMed
    43. Cherry MA, Bhardwaj H, Hopps S, Srour S, Pant S. Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report. J Oncol Pharm Pract. 2013 Sep; 19(3):261-4. PMID: 23135805.
      View in: PubMed
    44. Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. J Oncol Pharm Pract. 2013 Sep; 19(3):222-7. PMID: 23135806.
      View in: PubMed
    45. Alinari L, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RA. Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male. Head Neck Pathol. 2012 Dec; 6(4):496-501. PMID: 22711054.
      View in: PubMed
    46. Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012 Jul; 70(1):49-56. PMID: 22729159.
      View in: PubMed
    47. Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA. Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. Br J Haematol. 2010 Feb; 148(4):623-6. PMID: 19821825.
      View in: PubMed
    48. Pant S, Ramaswamy B. Association of major stressors with elevated risk of breast cancer incidence or relapse. Drugs Today (Barc). 2009 Feb; 45(2):115-26. PMID: 19343231.
      View in: PubMed
    49. Pant S, Chilukuri MP, Ramaswamy B. Docetaxel for the post-surgery treatment of patients with node-positive breast cancer. Ther Clin Risk Manag. 2008 Apr; 4(2):419-24. PMID: 18728853.
      View in: PubMed
    50. Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol. 2008 Mar 20; 26(9):1567-9. PMID: 18349415.
      View in: PubMed
    51. Pant S, Shapiro CL. Aromatase inhibitor-associated bone loss: clinical considerations. Drugs. 2008; 68(18):2591-600. PMID: 19093701.
      View in: PubMed
    52. Pant S, Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2007 Aug; 13(8):877-85. PMID: 17640590.
      View in: PubMed
    53. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy. 24:1150-1158.
    54. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 77:1275-1283.
    55. PARTNER. Oral Oncology. 61:31-40.
    56. Molecular targeted intervention for pancreatic cancer. Cancers. 7:1499-1542.
    57. Peer viewpoint. Journal of Supportive Oncology. 2:75-77.
    58. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 78:921-927.
    59. A Phase i Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. Cancer Investigation. 33:477-482.
    60. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors. Cancer. 121:1056-1063.
    PANT's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description